Q3 Revenue Falls 33% as Promo Credit and Inventory Constraints Bite; Nine-Month Sales Hit Record $4.3M
HYEX sits 68% above its 52-week low of $0.805.
Summary
Third-quarter net revenue fell 33% to $619,000 from $918,000 a year ago, dragged down by a one-time ~$300,000 promotional credit to a new major pharmacy retailer and temporary inventory constraints that limited planned shipments. The nine-month picture is stronger: revenue rose 53% to a record $4.3 million and gross margin expanded to 64.7% from 52.0%, helped by the Gummy USA merger and the Imaraïs Beauty acquisition. The bottom line deteriorated sharply — Q3 net loss widened to $1.7 million, or $(0.12) per share, from $395,000, or $(0.06), on higher interest expense, derivative fair-value changes and G&A from the acquisitions. Cash stood at just $143,000 at September 30, thin against the going-concern doubt and $5.4 million insider loan disclosed in the prior 10-Q, and this follows the September 18 8-K reporting director Bill Croyle's resignation, the third senior departure in two months. Management expects sequential growth to return in Q4 and reiterated an aspirational goal of more than 3x last year's annualized revenue run rate, but that is contingent on customer timing and market forces.
At the time of this announcement, HYEX was trading at $1.35 on OTC in the Life Sciences sector, with a market capitalization of approximately $19.9M. The 52-week trading range was $0.81 to $4.25. This news item was assessed with negative market sentiment and an importance score of 7 out of 10. Source: ACCESS Newswire.